Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

Hinxton

CRISPR Screening and Analysis

CRISPR screening, both pooled and arrayed, offers powerful tools for research and clinical discovery. While arrayed screening focuses on targeted gene editing to study specific [...]

Hinxton

Mitochondrial Medicine – Therapeutic Development

Mitochondrial disorders are now recognised as a significant cause of inherited disease. Progress toward new treatments relies on strong collaboration between clinicians, lab-based researchers, and [...]

Go to Top